Botox (Allergan brand of onabotulinumtoxinA, common alternates Dysport/abobotulinumtoxinA and Xeomin/incobotulinumtoxinA) is the most-studied aesthetic injectable in dermatology, with multiple Phase IV trials confirming consistent safety across Fitzpatrick IV-VI skin types. DermaVue Kochi administers Botox exclusively through MD DVL board-certified dermatologists, never delegated to technicians, which is the operative differentiator versus non-dermatologist aesthetic clinics where toxin handling and dilution errors are documented.
Brand selection is clinician-led based on diffusion preference and prior exposure. Allergan (Botox/onabotulinumtoxinA) is the reference product, precise placement, low diffusion, best for narrow targets (lip flip, gummy smile, fine-line treatment). Dysport (abobotulinumtoxinA) has faster onset and a wider diffusion pattern, best for broader fields (full forehead, masseter). Xeomin (incobotulinumtoxinA) is purified without complexing proteins, useful in patients with prior toxin exposure or antibody-formation concerns.
Standard dosing in Allergan unit equivalents: forehead horizontal lines 10-20U (onset 3-5d, duration 3-4mo); glabellar 20-25U (4-5mo); crow's feet 10-15U per side (3-4mo); masseter jaw-slim 20-40U per side (4-6mo); bunny lines 4-8U; hyperhidrosis 50-100U per axilla (6-12mo); gummy smile 2-4U; lip flip 4-6U; platysma neck bands 30-50U. Meaningful effect at 3-5 days, peak at 14 days (the 2-week review point at DermaVue), gradual offset over 3-6 months.
